CliffBio
small molecule

TRAVOPROST

TRAVOPROST

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRAVOPROST
Active ingredientTRAVOPROST
Strength0.004%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMay 2024
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.